This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Stock Market News for January 04, 2017
by Zacks Equity Research
Benchmarks finished in the green on the first trading day of 2017 as investors strived to make up for losses suffered during the last few sessions of profit booking
United Therapeutics' PAH Suite Bodes Well, Competition Rife
by Zacks Equity Research
On Dec 29, 2016, we issued an updated report on United Therapeutics Corporation (UTHR).
Biotech Stock Roundup: Conatus Soars on Novartis Deal, Early FDA Nod for Clovis Drug
by Arpita Dutt
Biotech stocks like Conatus (CNAT) and Clovis reported positive developments this week with one company signing a deal and the other getting accelerated FDA approval for its cancer treatment.
Gilead to Pay Merck $2.5B in HCV Patent Dispute, Stock Falls
by Zacks Equity Research
Gilead (GILD) has been ordered to pay $2.5 billion in royalties to Merck (MRK) in the largest patent infringement dispute in the history of the U.S.
Biotech Stock Roundup: Ophthotech Slumps on Fovista Results, Achaogen Skyrockets on Data
by Arpita Dutt
Several companies presented data this week with companies like Achaogen (AKAO) soaring while others like Ophthotech plunged.
The Zacks Analyst Blog Highlights: Gilead Sciences, Medtronic, NVIDIA, Accenture and Simon Property
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Gilead Sciences, Medtronic, NVIDIA, Accenture and Simon Property
Top Research Reports for NVIDIA, Medtronic & Gilead Sciences
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Gilead (GILD), Medtronic (MDT) and NVIDIA (NVDA).
The Zacks Analyst Blog Highlights: ExxonMobil, Gilead, Duke Energy, NVIDIA and Monster Beverage
by Zacks Equity Research
The Zacks Analyst Blog Highlights: ExxonMobil, Gilead, Duke Energy, NVIDIA and Monster Beverage
Top Research Reports for Exxon, Duke & Gilead
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including ExxonMobil (XOM), Gilead (GILD) and Duke Energy (DUK).
The Zacks Analyst Blog Highlights: Allergan, Gilead Sciences, Pfizer, Regeneron Pharmaceuticals and Lion Biotechnologies
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Allergan, Gilead Sciences, Pfizer, Regeneron Pharmaceuticals and Lion Biotechnologies
Pricing Issues Continue to Weigh on the Pharma Sector
by Zacks Equity Research
With generics and biosimilars on the rise, many pharma companies are looking towards new products to pick up the pace and make up for lost sales.
Company News for November 03, 2016
by Zacks Equity Research
Companies In The News are: GILD,AGN,CLX,EL
Gilead (GILD) Misses Q3 Earnings, Reiterates 2016 Guidance
by Madeleine Johnson
Gilead Sciences Inc. (GILD) just released its third quarter fiscal 2016 financial results, posting earnings of $2.70 (accounting for BNRI) and revenues of $7.4 billion.
Stock Market News for September 21, 2016
by Zacks Equity Research
Benchmarks finished slightly higher on Tuesday ahead of the two-day policy meetings of the Fed and Bank of Japan (BOJ) ending today
New Oracle, Gilead Sciences & TOTAL Research Reports
by Sheraz Mian
Today's must-read reports are for Total (TOT), Oracle (ORCL) and Gilead Sciences (GILD).
Stock Market News for August 25, 2016
by Zacks Equity Research
Research Reports for Facebook, DuPont, Gilead & Others
by Sheraz Mian
Today's must-read reports are for DuPont (DD), Facebook (FB) and Gilead (GILD).
Top 7 Research Reports for July 11, 2016
by Sheraz Mian
Today's must-read reports are for Gilead (GILD), Altria (MO) and Qualcomm (QCOM).
Stock Market News for July 07, 2016
by Zacks Equity Research
Benchmarks ended in the green on Wednesday after the FOMC minutes from June meeting showed that most of the Fed policymakers were in favor of keeping rates unchanged.
Top 6 Research Reports for June 29, 2016
by Sheraz Mian
Today's must-read reports are for Amgen (AMGN), Kraft Heinz (KHC) and United Parcel (UPS).
Stock Market News for May 02, 2016
by Zacks Equity Research
Benchmarks closed in the red on Friday following dismal earnings results, which had a negative impact on biotech stocks
5 Biotech Stocks to Bet on This Earnings Season
by Zacks Equity Research
The happening biotech sector should be a good bet for investors.
Making Sense of the Q1 Earnings Reports
by Sheraz Mian
The deceleration in negative estimate revisions could be a positive development on the earnings front.
Stock Market News for March 22, 2012
by Zacks Equity Research
Gains in healthcare and telecom stocks helped the benchmarks end marginally higher on Monday.
Stock Market News for March 16, 2016
by Zacks Equity Research
Benchmarks ended mostly in the red following losses in healthcare and biotech stocks. Further, continuing decline in oil prices also weighed on key U.S. indexes